MAP2K7 and cancer: This recommendation is based upon the Summary of Product Characteristics package inserts for these drugs.63, 64, 65, 66, 67, 68 The European Society of Cardiology position paper on cancer treatments and cardiovascular toxicity69 does not give specific recommendations related to BRAF inhibitor/MEK inhibitor.